NEWS RELEASE
Teijin and Axcelead
to Determine the Name of Drug Discovery Research JVTokyo, Japan, February 13, 2024 --- Teijin Limited and Axcelead, Inc. jointly announced today thatthey have decided to name their drug discovery research joint venture "Axcelead Tokyo West Partners,Inc." ("Axcelead TWP"), which is scheduled to be established and commence its operations on April
1, 2024,.
Axcelead TWP’s business will include supporting drug discovery-related activities from target
selection to the discovery of candidate compounds and related research activities. Axcelead TWPaims to grow as a comprehensive drug discovery support service provider by tapping into demand
from drug discovery players in Japan and overseas, leveraging the strengths of its solid foundation
based on the drug discovery expertise, knowledge, technologies and assets held by Teijin andAxcelead.
In promoting its business, Axcelead TWP will work closely with Axcelead Drug Discovery Partners,
an integrated drug discovery CRO (contract research organization) affiliated with Axcelead, to meetthe needs of diverse drug discovery players and provide high-quality solutions.
This basic agreement, which accords with Axcelead's concept of co-creating drug discovery platforms,
responds to the global trend of horizontal specialization in non-clinical research and new forms ofoutsourced research.
Teijin and Axcelead will proceed with preparations for the establishment of Axcelead TWP and thestart of its operations.

【Overview of the Joint Venture】
Name of the company

Axcelead Tokyo West Partners, Inc.

Head Office

4-3-2 Asahigaoka, Hino-shi, Tokyo

Date of establishment
and commencement of Scheduled on April 1, 2024
business
Investment Status

Axcelead, Inc. 51%
Teijin Limited 49%

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields ofenvironmental value; safety, security and disaster mitigation; and demographic change and increased
health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has
evolved into a unique enterprise encompassing three core business domains: high-performancematerials including aramid, carbon fibers and composites, and also resin and plastic processing, films,
polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and presymptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems aswell as packaged software and B2C online services for digital entertainment. Deeply committed to its
stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions,” Teijin aims
to be a company that supports the society of the future. The group comprises some 170 companies
and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales ofJPY 1,018.8 billion (USD 7.6 billion) and total assets of JPY 1,242.4 billion (USD 9.2 billion) in thefiscal year ending March 31, 2023.
About Axcelead
Axcelead represents a holding company as healthcare platformer which owns a group of companies
which are developing a world-class healthcare platform for drug discovery. Axcelead DDP, Japan’s
first integrated drug discovery CRO, functions as the core company of the Axcelead group that took
over Takeda Pharmaceutical Company Limited's drug discovery platform business in 2017. ARCALIS
has become Japan's only one-stop mRNA contract drug development and manufacturing organization(CDMO).
Axcelead also owns A-Digital which develops a drug discovery digital platform to increase drug
discovery efficacy by 100 times, and the American company, PassPort Technologies, Inc. in San
Diego, California (“PassPort”). PassPort is a company that develops combination products of active
pharmaceutical ingredients and medical devices based on next-generation transdermal drug delivery
technology. Axcelead will promote the drug discovery ecosystem in Japan and will make various
contributions to healthcare broadly and globally.
For more information on Axcelead, please visit the company’s website at https://www.axceleadhd.com
Press Contact
Investor and Public Relations Department
Teijin Limited
pr@teijin.co.jp
Corporate Communications Department
Axcelead, Inc.
contact@axcelead-hd.com